Share-based Payment Arrangement, Expense of Rein Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rein Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Rein Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,447,000, a 185% increase year-over-year.
  • Rein Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,100,000, a 67% increase year-over-year.
  • Rein Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,117,000, a 6.1% decline from 2023.
  • Rein Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,190,000, a 43% decline from 2022.
  • Rein Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,083,000, a 7.8% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Rein Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,100,000 $1,447,000 +$939,000 +185% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $1,161,000 $256,000 -$70,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,231,000 $264,000 +$114,000 +76% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,117,000 $133,000 -$137,000 -51% 01 Oct 2024 31 Dec 2024 10-K 07 Apr 2025 2024 FY
Q3 2024 $1,254,000 $508,000 +$279,000 +122% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $975,000 $326,000 +$26,000 +8.7% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $949,000 $150,000 -$241,000 -62% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,190,000 $270,000 -$154,000 -36% 01 Oct 2023 31 Dec 2023 10-K 07 Apr 2025 2024 FY
Q3 2023 $1,344,000 $229,000 -$213,000 -48% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,557,000 $300,000 -$228,000 -43% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $1,785,000 $391,000 -$298,000 -43% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $2,083,000 $424,000 -$183,000 -30% 01 Oct 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
Q3 2022 $2,266,000 $442,000 -$219,000 -33% 01 Jul 2022 30 Sep 2022 10-Q 13 Oct 2023 2023 Q3
Q2 2022 $2,485,000 $528,000 +$167,000 +46% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $2,318,000 $689,000 +$58,000 +9.2% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $2,260,000 $607,000 +$244,000 +67% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
Q3 2021 $2,016,000 $661,000 +$196,000 +42% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $1,820,000 $361,000 -$199,000 -36% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $2,019,000 $631,000 +$126,000 +25% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $1,893,000 $363,000 -$116,000 -24% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $2,009,000 $465,000 -$149,000 -24% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $2,158,000 $560,000 +$100,000 +22% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $2,058,000 $505,000 -$58,000 -10% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $2,116,000 $479,000 -$112,000 -19% 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
Q3 2019 $2,228,000 $614,000 +$26,000 +4.4% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $2,202,000 $460,000 -$874,000 -66% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $3,076,000 $563,000 -$204,000 -27% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $3,280,000 $591,000 -$72,000 -11% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q3 2018 $3,352,000 $588,000 -$28,000 -4.5% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,380,000 $1,334,000 +$1,061,000 +389% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $2,319,000 $767,000 +$570,000 +289% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $1,749,000 $663,000 01 Oct 2017 31 Dec 2017 10-K 29 Mar 2019 2018 FY
Q3 2017 $616,000 +$427,000 +226% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $273,000 +$106,000 +63% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $197,000 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q3 2016 $189,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $167,000 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2

Rein Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,117,000 -$73,000 -6.1% 01 Jan 2024 31 Dec 2024 10-K 07 Apr 2025 2024 FY
2023 $1,190,000 -$893,000 -43% 01 Jan 2023 31 Dec 2023 10-K 07 Apr 2025 2024 FY
2022 $2,083,000 -$177,000 -7.8% 01 Jan 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
2021 $2,260,000 +$367,000 +19% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 $1,893,000 -$223,000 -11% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $2,116,000 -$1,164,000 -35% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
2018 $3,280,000 +$1,531,000 +88% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
2017 $1,749,000 +$1,061,000 +154% 01 Jan 2017 31 Dec 2017 10-K 29 Mar 2019 2018 FY
2016 $688,000 +$62,000 +9.9% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 $626,000 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.